STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #734 by analyst upside · 2026-06-27
EIKN
Eikon Therapeutics, Inc.
Healthcare · Market Cap $620M · P/E 0x
ANALYST PRICE TARGET
+116.6%
implied upside to consensus target
Current Price $11.45
Consensus Target $24.8
Bull Target $32.0
Bear Target $5.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
2
Hold
0
Sell
1
52-Week Low $7.9
52-Week High $17.4
YTD Return -23.7%
FUNDAMENTALS
Market Cap $620M
P/E Ratio (TTM) N/A
Forward P/E -1.9x
EPS (TTM) $-7.30
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $7.9
52-Week High $17.4
Current Price $11.45
Bear Target $5.0
Bull Target $32.0
● Now $11.45 ● Target $24.8
TRADING DATA
Avg Volume 302K
YTD Return -23.7%
Analyst Count 5
Consensus Buy
Upside to Target +116.6%
Last Updated 2026-06-27

ANALYST SUMMARY

Eikon Therapeutics, Inc. (EIKN) is currently trading at $11.45 with a Wall Street consensus price target of $24.8, implying potential upside of 116.6% over the next 12 months. 5 analysts currently cover EIKN, with a consensus rating of Buy - 80% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $32.0, while the most cautious has a target of $5.0.

EIKN operates in the Healthcare sector with a market capitalisation of $620M. The stock is down 23.7% year-to-date and is currently trading near the lower end of its 52-week range of $7.9 – $17.4.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for EIKN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wedbush — Reiterated
Underperform → Underperform 2026-05-12 Building track record
Wedbush reit
Underperform → Underperform 2026-03-31 Building track record
Cantor Fitzgerald ● Initiated
Overweight 2026-03-02 40% win rate (10 calls)
JP Morgan ● Initiated
Overweight 2026-03-02 43% win rate (7 calls)
B of A Securities ● Initiated
Buy 2026-03-02 Building track record
Mizuho ● Initiated
Outperform 2026-03-02 Building track record
Morgan Stanley ● Initiated
Overweight 2026-03-02 Building track record
Wedbush ● Initiated
Underperform 2026-02-26 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
36
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →